中国1-69岁人群丙型肝炎病毒感染血清流行病学:全国横断面研究
2020年8月1日至2021年6月1日在中国160个国家级疾病监测点、120个县,采用分层三阶段整群随机抽样调查1-69岁人群91,971人,最终分析91,896份血样。抗-HCV抗体阳性223人(0.24%),加权患病率0.28%(95%CI 0.24-0.34);其中111人(49.8%)HCV RNA阳性,加权患病率0.15%(95%CI 0.11-0.20)。
要点
- 中国1-69岁人群抗-HCV抗体加权患病率为0.28%(95%CI 0.24-0.34)。
- 抗-HCV抗体阳性者中HCV RNA阳性比例为49.8%,加权患病率0.15%(95%CI 0.11-0.20)。
核心结论
- 调查结果证实中国在控制丙型肝炎流行方面取得了重要进展,但由于人口基数大,HCV感染者的绝对数量仍然可观,需要共同努力推进综合策略以进一步遏制丙型肝炎流行。
研究设计与样本
- 2020年8月1日至2021年6月1日在中国160个国家级疾病监测点、120个县,采用分层三阶段整群随机抽样方法选取1-69岁个体开展全国横断面调查。
- 对静脉血样本抗-HCV抗体检测阳性者进一步检测HCV RNA,采用泰勒级数线性化进行方差估计并计算点估计值和95%CI,患病率估计采用加权计算,全国HCV负担采用工作簿法估算。
主要发现
- 共调查91,971人,91,896份(99.9%)血样完成检测并纳入最终分析,参与者中位年龄33岁(IQR 15-52),男性39,627人(43.1%)、女性52,269人(56.9%),汉族75,170人(81.8%)、非汉族16,726人(18.2%)。
- 223人(0.24%)抗-HCV抗体阳性,加权患病率0.28%(95%CI 0.24-0.34)。
- 抗-HCV抗体阳性者中111人(49.8%)HCV RNA阳性,HCV RNA阳性比例为0.12%,加权患病率0.15%(95%CI 0.11-0.20)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: China has a substantial disease burden of hepatitis C virus (HCV) infection. We aimed to analyse the findings from a national seroepidemiology survey of viral hepatitis in 2020, providing insights into the current state of hepatitis C in China. METHODS: A national, cross-sectional survey was conducted in China using a stratified, three-stage cluster random sampling method to select individuals aged 1-69 years from 160 national disease surveillance points. Venous blood samples that tested positive for anti-HCV antibodies were further tested for HCV RNA. Point estimates and 95% CIs of anti-HCV antibody and HCV RNA prevalence were calculated using Taylor series linearisation for variance estimations. The prevalence estimates were adjusted using weighted calculations. National HCV burden was estimated by the workbook method. FINDINGS: From Aug 1, 2020, to June 1, 2021, 91 971 individuals were surveyed in 120 counties, with 91 896 (99·9%) blood samples tested and included in the final analysis. The median age of participants was 33 years (IQR 15-52), 39 627 (43·1%) participants were male, 52 269 (56·9%) were female, 75 170 (81·8%) were of Han ethnicity, and 16 726 (18·2%) were in non-Han ethnic groups. 223 (0·24%) individuals tested positive for anti-HCV antibodies, with weighted prevalence of 0·28% (95% CI 0·24-0·34). Among these, 111 (49·8%) tested positive for HCV RNA, resulting in an HCV RNA positive proportion of 0·12% and weighted prevalence of 0·15% (95% CI 0·11-0·20). We estimated 5·54 million individuals who were anti-HCV antibody-positive and 3·22 million with viraemic infections. INTERPRETATION: The survey findings confirm that China has made important progress in controlling the hepatitis C epidemic. However, the absolute number of individuals infected with HCV remains substantial due to the large population denominator. Concerted efforts are essential to promote a comprehensive strategy to further curb the hepatitis C epidemic. FUNDING: Major Science and Technology Special Project of China's 13th 5-Year Plan. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Li J, Pang L, Ding G, et al. Seroepidemiology of hepatitis C virus infection in people aged 1-69 years in China: a national, cross-sectional study. Lancet Public Health. 2025. PMID: 41223865. doi:10.1016/S2468-2667(25)00254-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。